Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JSB462 (Luxdegalutamide) + Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC
NCT07047118Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Jul 2025
- Primary completion
- Jul 2027
- Countries
- 15
01
Overview
A Phase 2 trial of luxdegalutamide in castration-resistant prostate cancer (CRPC), sponsored by Novartis. Started Jul 2025; status: active, not recruiting.
02
Drugs
luxdegalutamide
03
Conditions
castration-resistant prostate cancer (CRPC)
Beyond the preview
Go deeper on NCT07047118.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07047118.